Business Wire (May 3, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
218 people get ICAD articles and Market Currents by email alert.
Get email alerts on ICAD »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Jan 10, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Nov 25, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 5, 2012)
-
Medical Device Trades: 7 Stocks Under 5 BucksMike Havrilla • Mon, Jul 6, 2009
-
iCAD: Shares Up following GE Healthcare's AcquisitionDouglas Cress • Tue, Nov 27, 2007
-
Negative CAD Research Shouldn't Impact Hologics, iCADLaura Goldman • Thu, Apr 19, 2007
-
iCAD's CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, Oct 31, 2012
-
iCAD, Inc. Q4 2007 Earnings Call TranscriptThu, Mar 6, 2008
-
Business Wire (May 3, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 24, 2013)
-
Business Wire (Apr 15, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Jan 10, 2013)
-
Business Wire (Jan 7, 2013)
-
Business Wire (Nov 25, 2012)
-
Business Wire (Nov 8, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Oct 30, 2012)
-
Business Wire (Oct 29, 2012)
-
Business Wire (Oct 23, 2012)
-
Business Wire (Aug 14, 2012)
-
Business Wire (Aug 1, 2012)
ICAD vs. ETF Alternatives
Company Description
Currently, there's no company description for ICAD.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, April 29, 6:21 PM iCAD (ICAD): Q1 EPS of -$0.07 beats by $0.18. Revenue of $7.93M beats by $0.73M. (PR) Comment! [Earnings, Breaking News]
- Wednesday, March 20, 12:34 PM iCAD (ICAD +2.3%) FDA) gains after saying it's received FDA clearance for its new cervical applicator for use with its Xoft Axxent Electronic Brachytherapy System to deliver high dose rate brachytherapy for intracavitary treatment of cancer of the uterus and cervix. Comment! [Healthcare, On the Move]
- Tuesday, February 19, 6:16 PM iCAD (ICAD): Q4 EPS of -$0.15. Revenue of $7.8M (+18% Y/Y). Shares -1.4% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
-
Wednesday, February 13, 12:45 PM
Midday top 10 gainers: RSOL +76%. RCON +27%. TRLA +25%. PRLB +24%. RPXC +22%. PRO +18%. ICAD +17%. PES +13%. AMRI +12%. VG +11%.
Midday top 10 losers: LTRE -21%. EZCH -21%. RATE -19%. RAX -18%. CLF -18%. MPG -17%. FBN -17%. NAII -16%. ATOS -14%. ZN -13%. Comment! [On the Move] -
Friday, January 11, 12:45 PM
Midday top 10 gainers: UPIP +31%. KGJI +20%. INFY +17%. DNDN +15%. REDF +14%. FLML +14%. BBY +12%. SIFY +11%. ICAD +10%. BCRX +10%.
Midday top 10 Losers: NEWL -29%. ARQL -15%. YOD -15%. PDEX -12%. BV -11%. RGLS -10%. FARO -9%. CENX -9%. MY -9%. STXS -9%. Comment! [On the Move] -
Monday, November 5, 2012, 12:45 PM
Midday top 10 gainers: NVGN +50%. ICAD +43%. NTE +36%. HMNY +19%. BMRN +30%. OPTT +25%. VRNG +23%. EQU +15%. BEE +13%. BITA +12%.
Top 10 Losers: EBIX -22%. HGSH -19%. RDN -14%. PCYC -12%. MEAD -15%. VTUS -10%. PKBK -10%. COCO -9%. PGRX -9%. ENZ -9%. 1 Comment [On the Move] -
Wednesday, October 3, 2012, 12:45 PM
Midday top 10 gainers: SRPT +162%. BIOL +38%. VRNG +25%. OCN +16%. KFS +16%. ASPS +14%. SNFCA +12%. TRU +10%. HOV +10%. ICAD +10%.
Top 10 Losers: GST -21%. LEAP -16%. XRTX -15%. THTI -13%. PBM -12%. SSY -10%. HOLL -10%. KRA -10%. ATRS -9%. KIOR -9%. 2 Comments [On the Move] - Friday, April 16, 2010, 11:32 AM Image analysis firm iCAD (ICAD) +7.6% as FDA clearance may finally be near for its Veralook colonoscopy product. Usually a three-month process, the review has taken nearly a year at an overloaded FDA. Comment!
-
Jim Van Meerten
ICAD - ICAD Inc - deleted from SLO portfolio for TA from BarChart - http://bit.ly/2fvF2O - View all 0 replies
LATEST REPLIES
